| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $101,360 | 1 | 50 |
Sells | $314 | 1 | 50 |
| Bashan Dror | PRESIDENT AND CEO | 1 | $101,360 | 0 | $0 | $101,360 |
| Bar-Shalev Amos | director | 0 | $0 | 1 | $314 | $-314 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell …
Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $101,360 and sold $314 worth of Protalix BioTherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $163,886 and sold $314 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bashan Dror (PRESIDENT AND CEO) — $101,360.
The last purchase of 56,000 shares for transaction amount of $101,360 was made by Bashan Dror (PRESIDENT AND CEO) on 2025‑12‑19.
| 2025-12-19 | Bashan Dror | PRESIDENT AND CEO | 56,000 0.0729% | $1.81 | $101,360 | +35.55% | ||
| 2025-11-18 | Sale | Bar-Shalev Amos | director | 168 0.0002% | $1.87 | $314 | +22.34% | |
| 2025-06-10 | Schwartz Aharon | director | 129,000 0.1637% | $1.60 | $205,884 | +26.58% | ||
| 2023-10-19 | Bashan Dror | PRESIDENT AND CEO | 64,516 0.0878% | $1.40 | $90,484 | -17.12% | ||
| 2023-01-03 | Schwartz Aharon | director | 110,000 0.1979% | $1.42 | $155,815 | +30.66% | ||
| 2022-04-11 | Bashan Dror | President and CEO | 68,000 0.1528% | $1.50 | $102,000 | -19.15% | ||
| 2021-06-03 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 857,506 1.9156% | $2.25 | $1.93M | -48.20% | |
| 2021-06-02 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 61,211 0.1389% | $2.56 | $156,553 | -53.63% | |
| 2020-04-07 | Schwartz Aharon | director | 64,000 0.1994% | $2.43 | $155,264 | +53.33% | ||
| 2017-05-16 | Manor Moshe | President & CEO | 50,000 0.0383% | $0.81 | $40,500 | -20.48% | ||
| 2016-12-02 | Sale | Camber Capital Management LLC | 10 percent owner | 2.5M 2.5199% | $0.32 | $792,000 | +144.13% | |
| 2015-12-14 | Maimon Yossi | Vice President & CFO | 10,000 0.01% | $0.78 | $7,800 | -2.56% | ||
| 2015-10-19 | Camber Capital Management LLC | 10 percent owner | 4M 4.0937% | $1.00 | $4M | -18.37% | ||
| 2014-08-13 | Sale | Bronfeld Zeev | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | ||
| 2014-08-13 | Sale | Bio-Cell Ltd | 10 percent owner | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | |
| 2013-08-15 | Sale | Akirov Alfred | director | 2,330 0.0025% | $5.07 | $11,813 | -14.98% | |
| 2013-08-14 | Sale | Akirov Alfred | director | 110,000 0.1193% | $5.05 | $555,750 | -14.78% | |
| 2013-03-12 | Sale | Akirov Alfred | director | 10,000 0.0108% | $5.70 | $57,000 | -12.63% | |
| 2013-03-11 | Sale | Akirov Alfred | director | 18,300 0.0198% | $5.72 | $104,737 | -12.63% | |
| 2013-03-08 | Sale | Akirov Alfred | director | 16,898 0.0182% | $5.86 | $99,068 | -14.94% |
| Bashan Dror | PRESIDENT AND CEO | 188516 0.234% | $492,026.76 | 3 | 0 | <0.0001% |
| Bar-Shalev Amos | director | 0 0% | $0 | 1 | 1 | <0.0001% |
| Camber Capital Management LLC | 10 percent owner | 10775000 13.3732% | $28.12M | 1 | 1 | <0.0001% |
| FROST PHILLIP MD ET AL | 10 percent owner | 7610167 9.4452% | $19.86M | 2 | 25 | +14.01% |
| Shaaltiel Yoseph | Executive VP, R&D | 463754 0.5756% | $1.21M | 4 | 16 | <0.0001% |
| Schwartz Aharon | director | 303000 0.3761% | $790,830.00 | 3 | 0 | +36.86% |
| Manor Moshe | President & CEO | 50000 0.0621% | $130,500.00 | 1 | 0 | <0.0001% |
| Maimon Yossi | Vice President & CFO | 10000 0.0124% | $26,100.00 | 1 | 13 | <0.0001% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M | |
$3,858,993 | 22 | -9.81% | $192.38M |
| Increased Positions | 42 | +56.76% | 2M | +12.84% |
| Decreased Positions | 27 | -36.49% | 688,846 | -4.96% |
| New Positions | 12 | New | 731,010 | New |
| Sold Out Positions | 5 | Sold Out | 60,973 | Sold Out |
| Total Postitions | 89 | +20.27% | 15M | +7.88% |
| Blackrock, Inc. | $6,179.00 | 4.44% | 3.55M | +181,358 | +5.38% | 2025-09-30 |
| Opaleye Management Inc. | $4,490.00 | 3.23% | 2.58M | +3M | New | 2025-09-30 |
| Renaissance Technologies Llc | $2,289.00 | 1.64% | 1.32M | -299,603 | -18.55% | 2025-09-30 |
| Northern Trust Corp | $1,570.00 | 1.13% | 902,459 | -177,264 | -16.42% | 2025-09-30 |
| Geode Capital Management, Llc | $1,426.00 | 1.03% | 819,777 | -6,556 | -0.79% | 2025-09-30 |
| Stratos Wealth Partners, Ltd. | $870.00 | 0.63% | 500,000 | +150,000 | +42.86% | 2025-09-30 |
| State Street Corp | $867.00 | 0.62% | 498,547 | +54,308 | +12.22% | 2025-09-30 |
| Vanguard Group Inc | $808.00 | 0.58% | 464,421 | -20,377 | -4.2% | 2025-09-30 |
| Connor, Clark & Lunn Investment Management Ltd. | $697.00 | 0.5% | 400,398 | -95,818 | -19.31% | 2025-09-30 |
| Ubs Group Ag | $331.00 | 0.24% | 190,276 | +115,126 | +153.19% | 2025-09-30 |